Lindilane (Paracetamol, Codeine Phosphate Hemihydrate)

Paracetamol reduces pain and fever by inhibiting central cyclo‑oxygenase enzymes, lowering prostaglandin production. Codeine phosphate hemihydrate is converted in the liver to morphine, which binds to μ‑opioid receptors in the brain and spinal cord, enhancing analgesic effects through opioid pathways.

The appropriate dose of Lindilane is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and medical history. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of Lindilane in pregnancy or lactation depends on clinical judgment. Paracetamol is generally considered low risk, but codeine can cross the placenta and appear in breast milk. Healthcare providers should evaluate the risk‑benefit ratio before prescribing to pregnant or nursing individuals.

To request Lindilane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑ingredient paracetamol, Lindilane adds an opioid component, offering stronger pain relief for moderate to severe pain. Unlike stronger opioids such as morphine, it has a lower risk of respiratory depression but still requires careful monitoring for dependence and side effects.

Lindilane should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, heat and direct sunlight to maintain potency and stability throughout its shelf life.

Lindilane is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can reduce gastrointestinal discomfort. Swallow tablets whole; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious risks include respiratory depression, especially in opioid‑naïve patients or when combined with other depressants, severe allergic reactions (anaphylaxis), liver injury from excessive paracetamol, and the potential for dependence or abuse of the codeine component.

Lindilane is contraindicated in individuals with known hypersensitivity to paracetamol, codeine, or any excipients, those with severe respiratory insufficiency, acute or severe asthma, and patients taking monoamine oxidase inhibitors. Caution is also advised for patients with significant liver disease or a history of opioid dependence.